Zoloft — Class II drug recall D-0151-2018
Terminated recall by Pfizer Inc., reported 2018-01-10, distributed nationwide. SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent
| Recall number | D-0151-2018 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pfizer Inc., New York, NY, United States |
| Recall initiated | 2017-10-20 |
| Classified | 2018-01-04 |
| Reported by FDA | 2018-01-10 |
| Terminated | 2020-06-02 |
| Distributed | Nationwide (US) |
| Quantity | 1,972 bottles |
| Reason classes | potency |
| NDC | 00049-4960-30 |
| Lot numbers | S84026 |
Product
Zoloft (sertraline HCl) tablets 25 mg* 30-count bottle, Rx only, Distributed by Roerig Division of Pfizer Inc., NY, NY, 10017 NDC 0049-4960-30
Reason for recall
SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0151-2018. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.